Skip to main content
Journal of Translational Medicine logoLink to Journal of Translational Medicine
. 2025 Nov 11;23:1258. doi: 10.1186/s12967-025-07052-7

Correction: Targeting the MARCH5-MFN2 axis to enhance mitochondrial fusion and sensitize multiple myeloma cells to venetoclax

Ilenia Valentino 1, Maria Eugenia Gallo Cantafio 1,#, Roberta Torcasio 1,2,3,#, Pierpaolo Murfone 1, Ludovica Ganino 1, Alessia Gallo 4, Nicola Cuscino 4, Ida Perrotta 5, Federico Tallarigo 6, Maria Mesuraca 1, Massimo Gentile 7,8, Giuseppe Viglietto 1, Nicola Amodio 1,
PMCID: PMC12604398  PMID: 41219735

Correction to: J Transl Med 23, 917 (2025) 10.1186/s12967-025-06942-0

Following publication of the original article [1], the authors reported an error in Figure 3D. It was noticed that the label UQCRFS1 was missing form the right panel of the figure.

The incorrect version of Fig. 3 was:

graphic file with name 12967_2025_7052_Figa_HTML.jpg

The correct Fig. 3 is:

graphic file with name 12967_2025_7052_Fig3_HTML.jpg

The original article [1] has been updated.

Footnotes

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Maria Eugenia Gallo Cantafio and Roberta Torcasio have equally contributed to this work

Reference

  • 1.Valentino I, Gallo Cantafio ME, Torcasio R, et al. Targeting the MARCH5-MFN2 axis to enhance mitochondrial fusion and sensitize multiple myeloma cells to venetoclax. J Transl Med. 2025;23:917. 10.1186/s12967-025-06942-0. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Translational Medicine are provided here courtesy of BMC

RESOURCES